Mark Cuban Cost Plus Drug Company Stock

www.costplusdrugs.comHealthcare / Healthcare providers & servicesFounded: 2016

Mark Cuban Cost Plus Drug Company is a pharmaceutical drug developer and sales marketplace with a mission to provide affordable care options and increase access to medicine that everyday American citizens need. The medicines the company provides are listed at fixed, transparent profit margins so customers know exactly what their needed medication costs. Mark Cuban Cost Plus Drug Company was founded by Alexander Oshmyanksy in 2016 and is headquartered in Dallas, TX.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Mark Cuban Cost Plus Drug Company, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation
Private Market Pricing DetailsValuation & Financings

Enterprise Value

Powered by Forge Data

Access Mark Cuban Cost Plus Drug Company’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Animation displayed is not current and securities are shown for illustrative purposes only.

Mark Cuban Cost Plus Drug Company Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Mark Cuban Cost Plus Drug Company Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Mark Cuban Cost Plus Drug Company investors also invested in these private companies

Leadership & Board

Leadership

Alexander Oshmyansky Ph.D
Co-Founder & Chief Executive Officer
Mark Cuban
Co-Founder
Erin Albert
Chief Privacy Officer & Vice President, Pharmacy Relations

Mark Cuban Cost Plus Drug Company stock FAQs

plusminus

Can you buy Mark Cuban Cost Plus Drug Company stock?

As Mark Cuban Cost Plus Drug Company is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Mark Cuban Cost Plus Drug Company, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Mark Cuban Cost Plus Drug Company stock?

To invest in a private company like Mark Cuban Cost Plus Drug Company through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Mark Cuban Cost Plus Drug Company stock?

Yes, you may sell the Mark Cuban Cost Plus Drug Company stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Mark Cuban Cost Plus Drug Company stock?

If you hold private company shares of Mark Cuban Cost Plus Drug Company – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Mark Cuban Cost Plus Drug Company on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Mark Cuban Cost Plus Drug Company a public company?

No, Mark Cuban Cost Plus Drug Company is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Mark Cuban Cost Plus Drug Company’s stock price?

Mark Cuban Cost Plus Drug Company is a privately held company and therefore does not have a public stock price. However, you may access Mark Cuban Cost Plus Drug Company private market stock price with Forge Data.
plusminus

What is Mark Cuban Cost Plus Drug Company’s stock ticker symbol?

Mark Cuban Cost Plus Drug Company does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Mark Cuban Cost Plus Drug Company’s news and media highlights

Entrepreneur and investor Mark Cuban wants to "f--k up" the U.S. healthcare system to make it more affordable, the billionaire told "The Daily Show" host Jon Stewart this week. While the "Shark Tank" star acknowledged opportunities to have big ambitions in politics or raise prices to make more money from his upstart online pharmacy, Mark Cuban Cost Plus Drug Company, Cuban said he's more interested in disrupting healthcare to bring about long-term changes for the industry. “I don’t want to be 95 and look and say ‘I was president,’ but I didn’t get to know my kids at all. I’d rather say, ‘I f---ed up healthcare and everybody’s healthier and got a better world to live in,'" Cuban said to Stewart as a guest on his show this week.
Community Health Systems, Inc. (NYSE: CYH) ("CHS") announced today that it is expanding its partnership with Mark Cuban Cost Plus Drugs Company, making more medications available – at significantly lower costs – to the Company’s affiliated hospitals. This new phase of the partnership taps into the Cost Plus Drugs Marketplace, powered by GraphiteRx. The Marketplace offers hundreds of common medications at deeply discounted prices compared to many traditional pharmaceutical suppliers.
SmithRx, a transparent and 100% pass-through PBM, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), announced today that in 6 months, they have saved SmithRx clients more than $9.5 million in the autoimmune category alone. This milestone has been achieved by strategically sourcing the lowest net cost autoimmune medications, including impactful transitions to cost-effective alternatives through Cost Plus Drugs. This successful alliance combines SmithRx's patient-first approach with Cost Plus Drugs’ revolutionary drug pricing strategy to tackle the highest cost drug category for many employers.
Avanlee Care, the company behind the all-inclusive care coordination app Ava, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), which offers significant savings on medications, have teamed up to support unpaid family caregivers. This collaboration will provide a cost-effective care coordination app along with access to safe and affordable medications for caregivers and their loved ones. Ordering medications through the Cost Plus Drugs integration within the Avanlee Care App is convenient for caregivers. About 54 million people in the US provide unpaid care to their loved ones. Of these caregivers, 47% earn less than $50,000 annually, and 66% dip into their savings to cover costs. This financial strain stresses them and hampers their ability both to provide good care for their family and separately to hold a job.
Updated on: Oct 10, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price™ may rely on a very limited number of inputs in its calculation. Forge Price™ is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price™, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price™. Forge Price™ is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price™ is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price™ for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.